Abstract 13685: Combined Genetic Defects of Sitosterolemia and Familial Hypercholesterolemia
Satoru Takase,Hiroyuki Ishiura,Masaki Tanaka,Sachiko Okazaki,Mikio Takanashi,Chengcheng Li,Jingxuan Shi,Yoko Iizuka,Jun Mitsui,Shoji Tsuji,Takashi Kadowaki,Toshimasa Yamauchi,Hiroaki Okazaki,Satoru TakaseHiroyuki IshiuraMasaki TanakaSachiko OkazakiMikio TakanashiChengcheng LiJingxuan ShiYoko IizukaJun MitsuiShoji TsujiTakashi KadowakiToshimasa YamauchiHiroaki OkazakiDiabetes and Metabolic Diseases,The Univ of Tokyo Hosp,Tokyo,JapanNeurology,The Univ of Tokyo Hosp,Tokyo,Japan
DOI: https://doi.org/10.1161/circ.144.suppl_1.13685
IF: 37.8
2021-11-10
Circulation
Abstract:Background: Familial hypercholesterolemia (FH) is an inherited disorder caused by mutations in the genes in the LDL receptor pathway, including LDLR , PCSK9 , APOB, and ARH . Defective uptake of LDL by the liver increases plasma LDL-cholesterol (LDL-C) levels, leading to an increased risk of coronary heart disease. The differential diagnosis of FH includes sitosterolemia which is a rare autosomal recessive disorder caused by mutations in ABCG5 or ABCG8 . Case presentation: Here we present a rare case of sitosterolemia with a genetic diagnosis of FH. A 64-years-old woman, clinically diagnosed as FH with Achilles tendon thickness (>18 mm on X-ray imaging), had been taking statins only intermittently due to muscle pains. The combinatorial therapy with ezetimibe decreased her plasma LDL-C levels to around 90-250 mg/dL with variable adherence to statins and dietary management. Further addition of a PCSK9 inhibitor (evolocumab) was largely ineffective with plasma LDL-C levels of 90-190 mg/dL. A systemic medical evaluation revealed persistent joint pains of unknown etiology and slightly decreased platelet count. These clinical features led us to suspect sitosterolemia. Biochemical and genetic analyses: Plasma concentration of sitosterol was elevated (16.8 mg/dL). Genetic testing was performed after obtaining informed consent. All procedures were subjected to approval by the human genome, gene analysis research ethics committee of the University of Tokyo. In addition to a heterozygous missense mutation in LDLR (p.Arg115His), a homozygous nonsense mutation in ABCG5 (p.Tyr188Ter) was identified. No rare variants were found in PCSK9 nor ABCG8 . Conclusions: To our knowledge, this is the first case of a combined genetic defect of sitosterolemia and FH. Atypical clinical manifestations such as large fluctuations of LDL-C levels, unresponsiveness to a PCSK9 inhibitor, arthralgia, and a reduced platelet count led to the genetic diagnosis. Our case is informative in the perspective of precision medicine, highlighting the importance of systemic medical evaluation to select patients who will be benefited more from genetic testing as well as the necessity of future drug development for this rare and intractable disease.
cardiac & cardiovascular systems,peripheral vascular disease